unknown
Stage
1
Investors
About
Architect Therapeutics develops novel small molecule drug candidates using C-H bond activation chemistry to create diverse 3D scaffolds for targeting difficult disease drivers, focusing on immunology and oncology.
Explore Architect Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.